Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3...

|By:, SA News Editor

Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3 study related to its AEZS-130 drug for treating adult growth hormone deficiency. The company now plans to consult with the FDA regarding the submission of a new drug application (NDA).